(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Deciphera Pharmaceuticals, LLC
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Novartis
Blueprint Medicines Corporation
AB Science
Allakos Inc.
Novartis
Novartis
Adelphi Values LLC
Patara Pharma